[go: up one dir, main page]

CN102266551B - Interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals - Google Patents

Interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals Download PDF

Info

Publication number
CN102266551B
CN102266551B CN201110174918.4A CN201110174918A CN102266551B CN 102266551 B CN102266551 B CN 102266551B CN 201110174918 A CN201110174918 A CN 201110174918A CN 102266551 B CN102266551 B CN 102266551B
Authority
CN
China
Prior art keywords
vaccine
interleukin
gene
therapeutic
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201110174918.4A
Other languages
Chinese (zh)
Other versions
CN102266551A (en
Inventor
刘永庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weifang Kang Aurth Biological Technology Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510010040.9A priority Critical patent/CN104623688B/en
Priority to CN201110174918.4A priority patent/CN102266551B/en
Publication of CN102266551A publication Critical patent/CN102266551A/en
Application granted granted Critical
Publication of CN102266551B publication Critical patent/CN102266551B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses an interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals. The interleukin-4 therapeutic vaccine is a protein vaccine or coupling protein vaccine of any form prepared by taking the natural or artificially synthesized complete protein or protein fragment of interleukin-4 as an antigen; or the interleukin-4 therapeutic vaccine is a gene vaccine or fusion gene vaccine of any form prepared by taking the complete gene or gene fragment of interleukin-4 as the antigen gene or the major antigen gene. The IL (interleukin)-4 vaccine is used for performing active immunotherapy on a host, generally, the effective time lasts for about 2-3 months by immunization for the first time, the effective therapeutic time lasts for about half a year by secondary immunization, and recovery can be achieved by 1-3 times of immunotherapy. Compared with direct application of anti-IL-4 antibody for treatment, the invention has the characteristics of few times of application, low dose and the like, thereby greatly reducing the therapeutic cost, and also greatly reducing the possibility of generating allergic reaction.

Description

Can be used for the interleukin-4 therapeutic vaccine for the treatment of human or animal's immune related diseases
Technical field
The present invention relates to the interleukin-4 therapeutic vaccine that can be used for treating human or animal's immune related diseases.
Background technology
Up to the present, people still lack the chronic infectious disease caused by endotrophic pathogen (virus, antibacterial, parasite etc.) and more effectively treat way, and vaccine prevention effect is also undesirable.Theoretically, this kind of chronic infectious disease needs host to produce the reaction of a strong class (Th1) anti-infectious immunity could remove pathogen, but how to induce body to produce strong Th1 anti-infectious immunity to react and remain an individual difficult problem.The exploratory development long-term according to applicant finds, the clinical onset stage great majority of this kind of chronic infectious disease all show as very strong two classes (Th2) anti-infectious immunity reaction, namely react based on Th2 anti-infectious immunity; Subclinical infection then great majority all shows as very strong Th1 anti-infectious immunity reaction, namely reacts based on Th1 anti-infectious immunity.Further research proves, the generation of a class and the reaction of two para-immunities is not synchronous generation, complementary form, but mutually suppress, the form of rising one after another.IL-4 is that induction produces the immunoreactive major cytokine of Th2, if can reduce the content of IL-4 in host, can effectively suppress Th2 immunoreation, thus promote the immunoreactive generation of Th1.Experiment proves, injects anti-IL-4 antibody can reach this object to host.But due to the half-life of antibody shorter (half-life of IgG is about 21-28 days), needs repeated multiple times injection, not only increase cost, and easily cause allergic reaction.Be badly in need of a kind of with low cost and technological means that can not cause allergic reaction.
Summary of the invention
For above-mentioned prior art, the invention provides a class and prepare simple, the with low cost and safe and reliable interleukin-4 therapeutic vaccine that can be used for treating human or animal's immune related diseases.
The present invention is achieved by the following technical solutions:
Can be used for the interleukin-4 therapeutic vaccine for the treatment of human or animal's immune related diseases, be with the intact proteins of the natural of interleukin-4 or synthetic or protein fragments (polypeptide or oligopeptide, need before making vaccine further with other Antigenic macromolecules phase coupling) do any type of protein vaccine or coupling protein vaccine that antigen makes;
Or: do with the complete genome of interleukin-4 or genetic fragment any type of gene vaccine or fusion gene vaccine that antigen gene or major antigen gene make;
Or: with the complete genome of any carrier cloning IL-4 or genetic fragment, with the made gene vaccine of any expression system amplification gene, or express the intact proteins of IL-4 or protein fragments (polypeptide or oligopeptide) and do any type of protein vaccine or amalgamation protein vaccine that antigen makes; If selected expression vector belongs to live vector, also live vector recombinant vaccine can be made.
Medically conventional vaccine adjuvant can be added with in described vaccine.
Vaccine of the present invention not only can be used for treating the chronic infectious disease of human or animal and parasitic disease, also can be applied in anaphylaxis etc. and the Ia disease treatment of cancer, some type and go by further genralrlization.
Different according to prepared vaccine form, the embodiment of vaccine of the present invention can have multiple: as vaccines such as aluminium glue adjuvant, oily adjuvant, Liposome Adjuvants, can adopt the multitude of different ways such as subcutaneous injection, intradermal injection and intramuscular injection; If live vector vaccine, except above injection system, also can adopt the different modes such as oral, suction, collunarium, eye drip.
The present invention be directed to the defect existed in prior art: " injecting anti-IL-4 antibody to host; need repeated multiple times injection; not only increase cost, and easily cause allergic reaction ", and the technical scheme proposed, that is: the form of IL-4 vaccine is adopted to carry out active immunity treatment to host, generally, first immunisation can reach the effective time of about 2 ~ 3 months, and secondary immunity can reach effective treatment time of about half a year, through the immunization therapy of 1 ~ 3 time, the object of rehabilitation can be reached.With directly apply compared with anti-IL-4 Antybody therapy, have number of applications few, the features such as consumption is low, like this, not only greatly reduce treatment cost, and, greatly reduce and produce anaphylactoid probability.
Accompanying drawing explanation
Fig. 1: inoculate (see embodiment 1 below) the IL-4 gene recombinaton oil-adjuvant vaccine prepared by embodiment 1 respectively at first 3 weeks of induced hypersensitivity reaction and 1 week subcutaneous (s.c.) to experiment BALB/c mouse, separately establish pET-32 carrier oil Adjuvanted vaccines and normal saline immunized controls group.Low dosage (5 μ g) chicken ovalbumin (OVA) aluminium glue vaccine intraperitoneal inoculation is used respectively in the 0th week and the 3rd week, with sensitized mice, instilled by nostril, to induce generation anaphylaxis in the 5th week with high dose (80 μ g are dissolved in 50 μ l PBS) OVA.Result shows: IL-4 gene recombinaton oil-adjuvant vaccine immune group is compared with normal saline immunized controls group with pET-32 carrier oil Adjuvanted vaccines group, and IL-4 gene recombinaton oil-adjuvant vaccine significantly can reduce the generation of OVA-IgE specific antibody.
Fig. 2: give experiment BALB/c mouse respectively at before Li Shiman parasite inoculation 3 weeks and 1 week abdominal cavity (i.p.) inoculate (see embodiment 1 below) IL-4 gene recombinaton aluminium glue vaccine prepared by embodiment 1, separately establish pET-32 carrier aluminium glue vaccine and normal saline immunized controls group.Appropriate Li Shiman parasite subcutaneous (s.c.) injection inoculation is in mouse hind leg foot pad.Weekly by the pathological changes size at kind of calliper once pad place enough after inoculation, continue 8 ~ 10 weeks.Result shows, IL-4 genetic vaccine significantly can reduce the parasitic infection of Li Shiman.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further illustrated.
Embodiment 1: prepared by structure and the vaccine of mice IL-4 genetic vaccine
According to the full genome coded sequence of mice IL-4, design a pair suitable primer, by RT-PCR method amplification IL-4cDNA sequence.Then, through determined dna sequence, after the cDNA sequence that proof increases is accurate, be cloned into the suitable position of pET-32 fusion expression vector again, and further recombiant plasmid and pET-32 fusion expression vector blank plasmid are proceeded in suitable expression coli strain, through scale fermentation, extraction purification IL-4 fusion rotein and the sulfur hydrogen reduction albumen expressed by vehicle Control.It is [different according to the content of purification IL-4 fusion rotein after sulfur hydrogen reduction albumen expressed by purification IL-4 fusion rotein or vehicle Control is mixed by proper proportion from oily adjuvant or aluminium glue adjuvant etc., to oil-adjuvant vaccine, the volume ratio of oil/protein solution can be controlled in (1: 1) ~ (3: 1); To aluminium glue Adjuvanted vaccines, the volume ratio of aluminium glue/protein solution can be controlled in (1: 1) ~ (1: 5); Require that the amount of IL-4 fusion rotein or vehicle Control sulfur hydrogen reduction albumen in every part vaccine is about 15-20 μ g; The volume of every part vaccine is about 0.1ml; Or according to the preparation of veterinary's pharmacopeia rule of operation], experiment vaccine is made in further homogenate emulsifying (being undertaken by the rule of operation of refiner used).
Described oily adjuvant is by the pale yellow oily liquid body formed after the Span-80 of 94% (V/V) mineral oil (No. 10 white oils), 6% (V/V), 2% (g/V) aluminium stearate heating for dissolving; Oil adjuvant is the milky water-in-oil type vaccine of the thickness that vaccine protein solution and oily adjuvant are formed through emulsifying.General employing injection inoculation, being product conventional in prior art, is in animal inactivated vaccine, use wider adjuvant at present.
Described aluminium glue adjuvant also uses wider adjuvant in animal inactivated vaccine.
Embodiment 2: safety testing and the anaphylaxis of mice IL-4 genetic vaccine are tested
By the method for embodiment 1, after the sulfur hydrogen reduction albumen normal saline expressed by purification IL-4 fusion rotein or vehicle Control is suitably diluted with oily adjuvant or aluminium glue adjuvant by 1: 1 volume ratio be mixed with into IL-4 amalgamation protein vaccine or vehicle Control sulfur hydrogen reduction protein vaccine.The IL-4 amalgamation protein vaccine prepared divides low (0.1ml, about 1 part), in (0.25ml, about 2.5 parts), high (0.5ml, about 5 parts) three various dose groups immune BALB/c mouse respectively, separately establish pET-32 carrier bacterin and saline control group, often organize 5 mices, subcutaneous multi-point injection.3 weeks, interval, carries out second time and third time inoculation respectively.Observe after vaccine injection that mice has no adverse reaction, the phenomenon such as irritated, dead respectively.Result shows: physically well develop after mouse inoculation vaccine, and the mental status and appetite are all normal, and inoculation position has the untoward reaction such as transient swelling, heating, especially more obvious in high dose group performance.For oily adjuvant Seedling, high dose group mice, because vaccine absorbs comparatively slow, has slight granuloma to react.
Embodiment 3: mice IL-4 genetic vaccine strengthens the test of anti-tumor activity
By the method for embodiment 1, after the sulfur hydrogen reduction albumen normal saline expressed by the IL-4 fusion rotein of purification or vehicle Control is suitably diluted and aluminium glue adjuvant in 1: 1 ratio be mixed with and test or control vaccine.Require that the amount of IL-4 fusion rotein or vehicle Control sulfur hydrogen reduction albumen in every part vaccine is about 15 ~ 20 μ g; The volume of every part vaccine is about 0.1ml.To experiment mice respectively at tumor cell attack first 3 weeks and 1 week abdominal cavity (i.p.) inoculate IL-4 gene recombinaton aluminium glue vaccine prepared by embodiment 1, separately establish pET-32 carrier aluminium glue vaccine and normal saline immunized controls group.Check a tumor growth situation every 3 days after tumor inoculation, test end in 60 days.Result shows, IL-4 genetic vaccine significantly can reduce the incidence rate (see table 1) of tumor.
Table 1: mice IL-4 genetic vaccine strengthens the result of the test (often organize 10, data are survival rate %) of anti-tumor activity
Embodiment 4: the test of relapse rate after mice IL-4 genetic vaccine reduction tumor operation
By the method for embodiment 1, after the sulfur hydrogen reduction albumen normal saline expressed by the IL-4 fusion rotein of purification or vehicle Control is suitably diluted and aluminium glue adjuvant in 1: 1 ratio be mixed with and test or control vaccine.Require that the amount of IL-4 fusion rotein or vehicle Control sulfur hydrogen reduction albumen in every part vaccine is about 15-20 μ g; The volume of every part vaccine is about 0.1ml.To experiment mice respectively at the IL-4 gene recombinaton aluminium glue vaccine when same day after tumor operation and the 14th day prepared by intraperitoneal inoculation embodiment 1, separately establish pET-32 carrier aluminium glue vaccine and normal saline immunized controls group.Checked a tumor growth situation every 3 days after tumor operation, test and terminate after 100 days.Result shows, IL-4 genetic vaccine significantly can reduce the relapse rate (see table 2) of tumor.
Table 2: mice IL-4 genetic vaccine strengthens the result of the test (often organize 10, data are survival rate %) of anti-tumor activity
Embodiment 5: mice IL-4 genetic vaccine suppresses to breathe the anaphylactoid test of channel type
By the method for embodiment 1, after the sulfur hydrogen reduction albumen normal saline expressed by the IL-4 fusion rotein of purification or vehicle Control is suitably diluted with oily adjuvant in 1: 1 ratio be mixed with and test or control vaccine.Require that the amount of IL-4 fusion rotein or vehicle Control sulfur hydrogen reduction albumen in every part vaccine is about 15-20 μ g; The volume of every part vaccine is about 0.1ml.Inoculate the IL-4 gene recombinaton oil-adjuvant vaccine prepared by embodiment 1 respectively at first 3 weeks of induced hypersensitivity reaction and 1 week subcutaneous (s.c.) to experiment BALB/c mouse, separately establish pET-32 carrier oil Adjuvanted vaccines and normal saline immunized controls group.Low dosage (5 μ g) chicken ovalbumin (OVA) aluminium glue vaccine intraperitoneal inoculation is used respectively in the 0th week and the 3rd week, with sensitized mice, instilled by nostril, to induce generation anaphylaxis in the 5th week with high dose (80 μ g are dissolved in 50 μ l PBS) OVA.Result shows: IL-4 gene recombinaton oil-adjuvant vaccine immune group is compared with normal saline immunized controls group with pET-32 carrier oil Adjuvanted vaccines group, IL-4 gene recombinaton oil-adjuvant vaccine significantly can reduce the quantity (see table 3) of the oxyphil cell in the generation (see accompanying drawing 1) of OVA-IgE specific antibody and pulmonary branches trachea folliculus flushing liquor, and significantly suppresses the hypertrophy of goblet cell and the degree of histiocyte inflammation.
Table 3: mice IL-4 genetic vaccine suppresses the secretion of oxyphil cell in pulmonary branches trachea folliculus
Embodiment 6: the test of mice IL-4 genetic vaccine treatment murine chronic leishmaniasis
By the method for embodiment 1, after the sulfur hydrogen reduction albumen normal saline expressed by the IL-4 fusion rotein of purification or vehicle Control is suitably diluted and aluminium glue adjuvant in 1: 1 ratio be mixed with and test or control vaccine.Require that the amount of IL-4 fusion rotein or vehicle Control sulfur hydrogen reduction albumen in every part vaccine is about 15-20 μ g; The volume of every part vaccine is about 0.1ml.Give experiment BALB/c mouse respectively at before Li Shiman parasite inoculation 3 weeks and 1 week abdominal cavity (i.p.) inoculate IL-4 gene recombinaton aluminium glue vaccine prepared by embodiment 1, separately establish pET-32 carrier aluminium glue vaccine and normal saline immunized controls group.Appropriate Li Shiman parasite subcutaneous (s.c.) injection inoculation is in mouse hind leg foot pad.Weekly by the pathological changes size at kind of calliper once pad place enough after inoculation, continue 8 ~ 10 weeks.Result shows, IL-4 genetic vaccine significantly can reduce the parasitic infection of Li Shiman (see accompanying drawing 2).
Embodiment 7: mice IL-4 genetic vaccine strengthens the test lungy of mice preventing chronic
By the method for embodiment 1, after the sulfur hydrogen reduction albumen normal saline expressed by the IL-4 fusion rotein of purification or vehicle Control is suitably diluted and aluminium glue adjuvant in 1: 1 ratio be mixed with and test or control vaccine.Require that the amount of IL-4 fusion rotein or vehicle Control sulfur hydrogen reduction albumen in every part vaccine is about 15-20 μ g; The volume of every part vaccine is about 0.1ml.To experiment mice respectively at first 3 weeks of bacillus calmette-guerin vaccine (BCG) inoculation and 1 week abdominal cavity (i.p.) inoculate IL-4 gene recombinaton aluminium glue vaccine prepared by embodiment 1, separately establish pET-32 carrier aluminium glue vaccine and normal saline immunized controls group.Appropriate bacillus calmette-guerin vaccine is to mice subcutaneous (s.c.) or vein (i.v.) injection inoculation.Within after inoculation 12 ~ 16 weeks, attack (i.v. inoculation) with high dose recombinant BCG, then, within 10 ~ 12 weeks, get mouse spleen, grinding, filter, centrifugal, get appropriate single-cell suspension liquid to be taped against in agar version, insert in 37 DEG C of incubators and cultivate about 3 weeks, count colony counts on each flat board.Result shows, IL-4 genetic vaccine significantly can reduce the infection (see table 4) of BCG.
Table 4: mice IL-4 genetic vaccine strengthens mice preventing chronic result of the test lungy (often organize 10, data are bacterium colony average on each flat board)

Claims (2)

1. the application of interleukin-4 therapeutic vaccine in the medicine of the chronic leishmaniasis of preparation treatment, described interleukin-4 therapeutic vaccine is: 1. do with the intact proteins of the natural of interleukin-4 or synthetic any type of protein vaccine or coupling protein vaccine that antigen makes; Or: the intact proteins 2. expressing IL-4 with any expression system does any type of protein vaccine or amalgamation protein vaccine that antigen makes.
2. application according to claim 1, is characterized in that: be added with medically conventional vaccine adjuvant in described vaccine.
CN201110174918.4A 2011-06-27 2011-06-27 Interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals Active CN102266551B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510010040.9A CN104623688B (en) 2011-06-27 2011-06-27 It can be used for treating the interleukin-4 therapeutic vaccine of human or animal's tumor disease
CN201110174918.4A CN102266551B (en) 2011-06-27 2011-06-27 Interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110174918.4A CN102266551B (en) 2011-06-27 2011-06-27 Interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201510010040.9A Division CN104623688B (en) 2011-06-27 2011-06-27 It can be used for treating the interleukin-4 therapeutic vaccine of human or animal's tumor disease
CN201510009584.3A Division CN104623647A (en) 2011-06-27 2011-06-27 Therapeutic interleukin-4 vaccine capable of treating human or animal chronic tuberculosis

Publications (2)

Publication Number Publication Date
CN102266551A CN102266551A (en) 2011-12-07
CN102266551B true CN102266551B (en) 2015-05-13

Family

ID=45049131

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110174918.4A Active CN102266551B (en) 2011-06-27 2011-06-27 Interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals

Country Status (1)

Country Link
CN (1) CN102266551B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104826093A (en) * 2015-04-16 2015-08-12 刘永庆 Th2 immune response antagonist for treating chronic infectious hepatopathy, and yolk antibody thereof
CN108030916A (en) * 2015-07-03 2018-05-15 刘永庆 The Th2 immune responses inhibitor of anti-curing oncoma and/or chronic tuberculosis disease and its application
CN108324948A (en) * 2018-03-28 2018-07-27 潍坊康奥思生物技术有限公司 Application of the Th2 immune responses inhibitor in preparing treatment and/or preventing cancer drug

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1703239A (en) * 2002-10-09 2005-11-30 遗传工程与生物技术中心 Vaccine composition comprising interleukin-15 (IL-15)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1703239A (en) * 2002-10-09 2005-11-30 遗传工程与生物技术中心 Vaccine composition comprising interleukin-15 (IL-15)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
孙卫民等.第四节 白细胞介素4.《细胞因子研究方法》.1999,第418-432页. *
鸡白细胞介素4基因的克隆及其原核表达;戴华等;《中国预防兽医学报 》;20080630;第30卷(第6期);摘要,第473页左栏第1段-右栏第1段,第474页左栏倒数第3段-右栏第5段,第476页右栏倒数第2段-第477页左栏第4段 *

Also Published As

Publication number Publication date
CN102266551A (en) 2011-12-07

Similar Documents

Publication Publication Date Title
BR112022013573A2 (en) UNIVERSAL VACCINES AGAINST IMMUGENS FROM PATHOGENIC ORGANISMS THAT PROVIDE SPECIFIC PROTECTION FOR ORGANISMS AND BETWEEN GROUPS
Zhang et al. Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice
CN103768595B (en) Zoledronic acid adjuvant and the vaccine containing zoledronic acid adjuvant
CN102166356A (en) Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same
CN102266551B (en) Interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals
CN104371025A (en) Immunogenic protein aiming at cervical cancer and application of immunogenic protein
Jin et al. N-2-Hydroxypropyl Trimethyl Ammonium Chloride Chitosan-Aluminum Nano-Adjuvant Elicit Strong Immune Responses in Porcine Epidemic Diarrhea Inactivated Vaccine
Osorio et al. Immune responses to hepatitis B surface antigen following epidermal powder immunization
CN104623647A (en) Therapeutic interleukin-4 vaccine capable of treating human or animal chronic tuberculosis
CN102127554A (en) Japanese encephalitis particle vaccine and preparation method and application thereof
KR20180017554A (en) DNA vaccine for prevention and treatment of fish viral hemorrhagic septicemia
CN104117072B (en) Multivalent adenovirus vaccine for preventing toxoplasmosis
CN104623688A (en) Therapeutic interleukin-4 vaccine capable of treating human or animal tumor diseases
CN114366810B (en) A natural microorganism and plant-derived composite dual adjuvant capable of efficiently inducing humoral and cellular immunity, and its preparation method and application
Ibrahim et al. Preparation of combined inactivated oil Adjuvanted Pasteurella spp. and Clostridium spp. vaccine (Pneumoclost) in sheep
CN116785418A (en) Fish-source streptococcus agalactiae subunit vaccine and preparation method and application thereof
CN109022522B (en) GFP-2 small peptide and preparation method and application thereof
Olitzki et al. Immunological studies on bovine leptospirosis
CN102212120A (en) Salmonella paratyphi A PagC subunit vaccine and preparation method thereof
CN101838325B (en) Pig antigen-presenting protein and its coding gene and application
CN101675994B (en) Therapy vaccine preparation
CN104922659A (en) Th2 immunoreaction inhibitor for preventing and treating tumors and/or chronic tuberculosis and application thereof
CN105497890A (en) Application of alpine yarrow herb polysaccharide as vaccine adjuvant
CN105381458A (en) Application of cationic polymer serving as vaccine adjuvant
CN103520717B (en) Alanine is as the application of vaccine adjuvant

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190227

Address after: 261041 South of Healthy East Street, Weifang High-tech Zone, Shandong Province, to the east of No. 2 High-tech Road (Room K711, Weifang Biomedical Science Park)

Patentee after: Weifang Kang Aurth Biological Technology Co. Ltd.

Address before: 250022 Sunshine 100D3-3-702, Sunshine New Road, Lixia District, Jinan City, Shandong Province

Patentee before: Liu Yongqing

TR01 Transfer of patent right